TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12386637
Drug: Body weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight-based 800/1000/1200 mg/d ribavirin
Study: 12386637
Drug: 13 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 mg/kg per day ribavirin
Study: 7561805
Drug: PM vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM vaccine (Pasteur Mérieux)
Study: 7561805
Drug: SKB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKB vaccine (Smith‐Kline Beecham)
Study: 2140854
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg loading dose: 4 mg IV plus 4 mg orally, followed by 8 mg every 8 hours orally for 3 to 5 days)
Study: 2140854
Drug: Metoclopramide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (80 mg loading dose: 60 mg IV plus 20 mg orally, followed by 20 mg every 8 hours orally for 3 to 5 days)
Study: 30569245
Drug: AB928 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB928 (10 to 200 mg once daily and 100 mg twice daily)
Study: 23835673
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 μg/kg)
Study: 23507173
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g GOS (Control)
Study: 23507173
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g GOS
Study: 23507173
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g GOS
Study: 21205361
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural body image therapy (10 group sessions)
Study: 19667282
Drug: 6-month therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-month therapy
Study: 19667282
Drug: 9-month therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-month therapy
Study: 15276392
Drug: Aspirin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75 mg/day) + Clopidogrel (75 mg/day)
Study: 15276392
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg/day) alone
Study: 11689577
Drug: Capecitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1,250 mg/m² administered twice daily days 1 to 14 every 3 weeks
Study: 11689577
Drug: Intravenous 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous 5-FU plus leucovorin (5-FU/LV)
Study: 31078146
Drug: M4E4 primer
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: M4E4 primer combination
Study: 31078146
Drug: M2E3 primer
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2E3 primer combination
Study: 31078146
Drug: M4E3 primer
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: M4E3 primer combination
Study: 31078146
Drug: M3E1 primer
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3E1 primer combination
Study: 31078146
Drug: M2E4 primer
Normalized name: Primor
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2E4 primer combination
Study: 29873529
Drug: HTX-019 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-019 130 mg (30-min infusion)
Study: 29873529
Drug: fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosaprepitant 150 mg (20- or 30-min infusion)
Study: 20081109
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (0.7 pmol.kg(‐1).min(‐1))
Study: 26540491
Drug: Tiotropium Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat 2.5 or 5 μg
Study: 23992515
Drug: Tiotropium HandiHaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium HandiHaler 18 μg
Study: 23913464
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control strategy (antiarrhythmic medication and/or electrical cardioversion)
Study: 17090821
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow mesenchymal stem cell therapy
Study: 15001902
Drug: Phenoxybenzamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine 0.25 mg/kg on cardiopulmonary bypass
Study: 9374816
Drug: High hydration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hydration (HighH) - 2.0 ml water/kg body weight every 30 min
Study: 9374816
Drug: Low hydration
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hydration (LowH) - 0.25 ml water/kg body weight every 30 min
Study: 3539523
Drug: PEEP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP titration based on PaO2 < 65 torr with FIO2 of 0.45
Study: 3539523
Drug: PEEP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP titration until PaO2/FIO2 > 300 or Qsp/Qt < 0.20
Study: 28603468
Drug: Formulated milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated milk product containing 9 g milk protein (FMP)
Study: 18327986
Drug: darunavir/r (600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/r (600/100 mg bid)
Study: 16801663
Drug: Haplotypes ‐2578‐A/‐1154‐A/‐634‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haplotypes ‐2578‐A/‐1154‐A/‐634‐G or ‐2578‐A/‐1154‐G/‐634‐G in the VEGF gene
Study: 10946892
Drug: 1% T
Normalized name: OPIUM 1% TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% T gel (50 or 100 mg/day)
Study: 10946892
Drug: 1% T
Normalized name: OPIUM 1% TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% T gel (100 mg/day)
Study: 10946892
Drug: 1% T
Normalized name: OPIUM 1% TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% T gel (50 mg/day)
Study: 10946892
Drug: T patch
Normalized name: Icy Hot Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: T patch (5 mg/day)
Study: 10946892
Drug: 1% T
Normalized name: OPIUM 1% TINCTURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% T gel
Study: 15477371
Drug: T patch
Normalized name: Icy Hot Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: T patch
Study: 1457767
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg three times daily)
Study: 6749206
Drug: Conventional high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high-dose prednisone
Study: 6749206
Drug: Cytotoxic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic drugs
Study: 25666998
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200mg/mL weekly for five weeks)
Study: 23085502
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy home program (OTHP) for 20 weeks, average 15 min per session
Study: 21095115
Drug: CNS-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS-directed therapy with intravenous methotrexate (5 g/sqm) in 4-10 courses and intrathecal methotrexate injections (10-20), no cranial irradiation.
Study: 19011778
Drug: Low-molecular-weight hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight hydroxyethyl starch (HES) at 2 ml x kg(‐1) x h(‐1) during surgery and 1 ml x kg(‐1) x h(‐1) after surgery, plus acetated Ringer's solution (AR) to maintain CVP at 5 mm Hg
Study: 19011778
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution (AR) to maintain CVP at 3-5 mmHg
Study: 19011778
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution (AR)
Study: 16980114
Drug: Inactivated whole-virion
Normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole-virion influenza A (H5N1) vaccine with 1.25 microg (24), 2.5 microg (24), 5 microg (24), or 10 microg (24) haemagglutinin per dose with aluminium hydroxide adjuvant
Study: 10676669
Drug: L-arginine 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 9 g daily for one month
Study: 26331581
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg single oral dose administered twice to subjects with ESRD, once before hemodialysis and once after hemodialysis)
Study: 26331581
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg single oral dose administered before and after hemodialysis)
Study: 26331581
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg single oral dose)
Study: 21626819
Drug: Axamon (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axamon (20 mg 3 times a day for 12 weeks)
Study: 15896281
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus continued psychopharmacology
Study: 11735172
Drug: levamisole/UFT chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole/UFT chemotherapy (N=29)
Study: 9440632
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day lansoprazole
Study: 8306000
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEDLINE and selective hand search
Study: 3597149
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy and misonidazole (1.5 gm/m2 daily 4‐6 hr before each treatment)
Study: 3597149
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy and misonidazole
Study: 30092666
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg dexmedetomidine via intravenous pump
Study: 18692841
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA) 100 mg daily
Study: 18692841
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids 4 g daily
Study: 17229604
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream monotherapy (Group B)
Study: 17229604
Drug: Combined ablation
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ablation followed by topical imiquimod (Group C)
Study: 12663600
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg (A10)
Study: 12663600
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (A80)
Study: 10979057
Drug: Warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone (INR maintained at 1.4 or more)
Study: 10979057
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and aspirin (75 mg/d)
Study: 9024712
Drug: NFL (Mitoxantrone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NFL (Mitoxantrone, 5-fluorouracil, high dose leucovorin)
Study: 3595067
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide‐5‐mononitrate (IS‐5MN)
Study: 3595067
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg isosorbide‐5‐mononitrate (IS‐5MN)
Study: 27845765
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (OT) administration
Study: 22207098
Drug: Daily care
Normalized name: Aveeno Baby Daily Care Set KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily care activities (washing, dressing, transfer)
Study: 16138670
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection plus casting
Study: 11806988
Drug: Conventional 4-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 4-drug induction with cyclophosphamide
Study: 11806988
Drug: Induction intensification
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction intensification (8-drug consolidation)
Study: 3224162
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral propranolol every 6 hours (test dosage form)
Study: 26754586
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg pitavastatin daily + intensive lifestyle modification (LSM)
Study: 25762232
Drug: Daptomycin 10
Normalized name: daptomycin 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 10 mg/kg/24 h intravenous plus fosfomycin 2 gr/6 g intravenous
Study: 25762232
Drug: Daptomycin 10
Normalized name: daptomycin 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin 10 mg/kg/24 h intravenous
Study: 18806109
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/d) for 6 months
Study: 18806109
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (10 mg/d) for 6 months
Study: 12542723
Drug: acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose 100 mg t.i.d.
Study: 12542723
Drug: glibenclamide 1
Normalized name: glibenclamide 1.25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide 1 mg t.i.d.
Study: 9014669
Drug: General prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: General prophylaxis with unfractionated heparin
Study: 9014669
Drug: General prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: General prophylaxis with low molecular weight heparin (LMWH)
Study: 9014669
Drug: Selective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective treatment of DVT after confirmation of diagnosis
Study: 1642678
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of clentiazem (30 mg)
Study: 1642678
Drug: Repeated administration
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated administration of clentiazem (30 mg daily for 2 weeks)
Study: 24908970
Drug: High-dose tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tamoxifen therapy in combination with chemotherapy
Study: 28912956
Drug: SRT2104 (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (2.0 g/day)
Study: 20837462
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 plus carboplatin AUC 6 for 4 cycles followed by maintenance pemetrexed
Study: 20837462
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 plus carboplatin AUC 6 plus bevacizumab 15 mg/kg for 4 cycles followed by maintenance bevacizumab
Study: 16883902
Drug: Tiepi Fengdou
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiepi Fengdou Capsule (TFC)
Study: 16883902
Drug: Shengmai Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai Capsule (Control)
Study: 11762816
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate 90 mg monthly
Study: 11762816
Drug: Oral clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clodronate 1,600 mg daily
Study: 11762816
Drug: Intravenous clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clodronate followed by oral clodronate
Study: 3565931
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of isotonic saline
Study: 24259556
Drug: Zinc citrate
Normalized name: Zinc Citrate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc citrate (10 mg)
Study: 24259556
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (10 mg)
Study: 24259556
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide (10 mg)
Study: 23202814
Drug: Methods video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methods video (focused on intrauterine device and contraceptive implant)
Study: 17664051
Drug: Naltrexone 150
Normalized name: METHYLNALTREXONE 150MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 150 mg/day for 12 weeks
Study: 10029562
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (3.0 ng x min‐1 x kg‐1 for 30 min followed by dose increment every 30 min until mean blood pressure increased by 25 mmHg)
Study: 10029562
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (10(‐9), 10(‐8), 10(‐7) mol/l) in cultured human vascular endothelial cells
Study: 10029562
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (AT1 receptor inhibitor)
Study: 10029562
Drug: Actinomycin D
Normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actinomycin D (RNA synthesis inhibitor)
Study: 10029562
Drug: Cycloheximide (protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycloheximide (protein synthesis inhibitor)
Study: 453298
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg initially, followed by 275 mg every 6 hours as needed)
Study: 31307843
Drug: EAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAA supplementation (15 g daily)
Study: 31307843
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (supervised progressive vigorous treadmill walking 3 times weekly)
Study: 29538089
Drug: Treatment Responders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Responders (TRs)
Study: 29538089
Drug: Treatment Nonresponders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Nonresponders (TNRs)
Study: 29538089
Drug: Medication-assisted treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-assisted treatment
Study: 29538089
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment nonresponse
Study: 29538089
Drug: Baseline SUD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline SUD treatment
Study: 24614377
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (400/100 mg BID)
Study: 24614377
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose (600/150 mg BID)
Study: 24614377
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (400/100 mg BID) after childbirth
Study: 24614377
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose (600/150 mg BID) after childbirth
Study: 15895892
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight HA (Hylan G‐F 20) injections
Study: 15895892
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight HA (Orthovisc) injections
Study: 15895892
Drug: Both HA
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both HA preparations (High molecular weight and Low molecular weight)
Study: 7340376
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg.kg‐1
Study: 7340376
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 μg.kg‐1
Study: 7340376
Drug: Fentanyl 30
Normalized name: fentaNYL 300 mcg oral lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 30 μg.kg‐1
Study: 6429481
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 17 beta-oestradiol 2 mg plus oestriol 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg plus oestriol 0.5 mg for 6 days
Study: 6429481
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 12 days, followed by 17 beta-oestradiol 2 mg plus norethisterone acetate 1 mg for 10 days, and then 17 beta-oestradiol 1 mg for 6 days (without oestriol)
Study: 29284788
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 Curry
Study: 29284788
Drug: Dose 2
Normalized name: Fluzone High-Dose 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 Curry
Study: 29284788
Drug: Dose 0
Normalized name: Femhrt Low Dose 0.5/2.5 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 0 Control
Study: 26517858
Drug: Duloxetine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (titrated up to 120 mg/day)
Study: 24255991
Drug: Bathing in
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bathing in geothermal seawater combined with NB‐UVB therapy three times a week
Study: 24255991
Drug: Intensive daily
Normalized name: OATMEAL 2 g in 100 g TOPICAL CREAM [ECZEMA INTENSIVE DAILY RELIEF BODY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive daily treatment involving bathing in geothermal seawater combined with NB‐UVB therapy
Study: 24255991
Drug: NB‐UVB therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB therapy alone three times a week